EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)Randomisierte kontrollierte StudieOpen Access

The Effect of a 5-Day Course of Azithromycin on Streptococcus Pneumoniae Carriage and Antimicrobial Resistance Among Kenyan Children Discharged From Hospital

Tanya E Libby iD, Angela Karani, Kirkby D Tickell iD, Donald Akech iD, Benson Singa, Doreen Rwigi iD, Kevin Kariuki iD, Nancy Onamu, Derrick Ounga, James A Berkley, Judd L Walson iD, J Anthony G Scott iD und 1 weitere

The Journal of Infectious Diseases · 2026

DOI: 10.1093/infdis/jiag028 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Tanya E Libby und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, University of Washington, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Azithromycin, Carrier State, Drug Resistance, Bacterial. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NICHD NIH HHS, NIEHS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mass azithromycin distribution reduces child mortality in some settings, potentially through reductions in nasopharyngeal carriage of Streptococcus pneumoniae, but has been associated with increased antimicrobial resistance. Individual-level data are lacking on the impact of azithromycin on antimicrobial resistance over time.

Methods

We analyzed data from a double-blind, randomized placebo-controlled trial (ClinicalTrials.gov; NCT02414399) which followed 1398 hospitalized Kenyan children to evaluate the impact of a 5-day course of oral azithromycin at discharge from hospital on pneumococcal carriage and the proportion of isolates (among a random sample) resistant to azithromycin. Randomization to azithromycin or placebo (1:1) was stratified by enrollment county (Kisii or Homa Bay). Using generalized estimating equations, we calculated prevalence ratios (PRs) and 95% CIs for the intervention, adjusting for enrollment site.

Results

Overall, 1253/1398 (89.6%) enrolled children received antibiotics during their hospitalization. Pneumococcal carriage at discharge was similar among children randomized to the azithromycin group (158/702 [22.5%]) compared with the placebo group (171/696 [24.6%]; P = .4) and did not differ at month 3 (65.6% versus 67.0%; PR: 0.98 [0.90, 1.06]) or month 6 (66.7% versus 66.5%; PR: 1.00 [0.92, 1.08]). At discharge, 15.7% of isolates were resistant to azithromycin and there was no difference between azithromycin-treated and placebo groups at month 3 (35/266 [13.2%] versus 32/256 [12.5%]; PR: 1.06 [0.86, 1.66]) or month 6 (41/245 [16.7%] versus 43/243 [17.6%]; PR: 1.01 [0.69, 1.49]).

Conclusions

Azithromycin treatment did not effect pneumococcal carriage or antimicrobial resistance 3- or 6-months post-randomization. High inpatient antibiotic use in this recently discharged population may have reduced any further impact of azithromycin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsAzithromycinCarrier StateDrug Resistance, BacterialPneumococcal InfectionsStreptococcus pneumoniaeChildChild, PreschoolFemaleHumansInfantMaleDouble-Blind MethodKenyaNasopharynxPatient Discharge

Stichwörter der Autor:innen

Kenyaantimicrobial resistanceazithromycinchildrenpneumococcus

Substanzen

Anti-Bacterial AgentsAzithromycin

Autor:innen und Institutionen

  • Department of Epidemiology, University of Washington, Seattle, Washington, USA.
  • Kenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Kilifi, Kenya.
  • Department of Global Health, University of Washington, Seattle, Washington, USA.
  • Kenya Medical Research Institute, Nairobi, Kenya.
  • Centre for Tropical Medicine & Global Health, University of Oxford, Oxford, United Kingdom.
  • Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

ORCID-Profile: Tanya E Libby, Kirkby D Tickell, Donald Akech, Doreen Rwigi, Kevin Kariuki, Judd L Walson, J Anthony G Scott

Förderung

  • NIAID NIH HHS
  • NICHD NIH HHS
  • NIEHS NIH HHS
  • NIH HHS
  • NIH National Institute of Allergy and Infectious Diseases (NIAID)
  • NIH National Institute of Environmental Health Sciences
  • Bill and Melinda Gates Foundation
  • National Institutes of Health

Zitieren

APA

Libby, T. E., Karani, A., Tickell, K. D., Akech, D., Singa, B., Rwigi, D., Kariuki, K., Onamu, N., Ounga, D., Berkley, J. A., Walson, J. L., Scott, J. A. G., & Pavlinac, P. B. (2026). The Effect of a 5-Day Course of Azithromycin on Streptococcus Pneumoniae Carriage and Antimicrobial Resistance Among Kenyan Children Discharged From Hospital. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiag028

Vancouver

Libby TE, Karani A, Tickell KD, Akech D, Singa B, Rwigi D, et al. The Effect of a 5-Day Course of Azithromycin on Streptococcus Pneumoniae Carriage and Antimicrobial Resistance Among Kenyan Children Discharged From Hospital. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiag028

BibTeX
@article{Libby2026,
  author = {Libby, Tanya E and Karani, Angela and Tickell, Kirkby D and Akech, Donald and Singa, Benson and Rwigi, Doreen and Kariuki, Kevin and Onamu, Nancy and Ounga, Derrick and Berkley, James A and Walson, Judd L and Scott, J Anthony G and Pavlinac, Patricia B},
  title = {The Effect of a 5-Day Course of Azithromycin on Streptococcus Pneumoniae Carriage and Antimicrobial Resistance Among Kenyan Children Discharged From Hospital},
  journal = {The Journal of Infectious Diseases},
  year = {2026},
  doi = {10.1093/infdis/jiag028}
}
Kostenlos starten →